Results 61 to 70 of about 7,431 (174)

Equivalence of freeze-dried and liquid-frozen formulations of MVA-BN as smallpox and mpox vaccine

Human Vaccines & Immunotherapeutics
Modified Vaccinia Ankara Bavarian Nordic (MVA-BN) as a smallpox and mpox vaccine has been approved in its liquid-frozen (LF) formulation in the US, Canada, and EU. A freeze-dried (FD) formulation may offer additional benefits, such as a longer shelf life
Richard N. Greenberg, Darja Schmidt, Daniela Reichhardt, Siegfried Roesch, Sanja Vidojkovic, Jane Maclennan, Liddy M. Chen, Robert Gruenert, Christian Kreusel, Heinz Weidenthaler, Thomas P.H. Meyer, Paul John Chaplin   +11 more
doaj   +1 more source

Tertiary Lymphoid Structures in Tuberculosis: Persistence, Protection, and Pathology

Immunological Reviews, Volume 333, Issue 1, August 2025.
ABSTRACT Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), is a major public health burden responsible for over a million deaths each year. A deeper understanding of the mechanisms that balance protective immunity and immunopathology is essential for developing more effective therapeutics.
Tiphaine M. N. Camarasa, Lorenzo Iseppi, David Schreiner, Carolyn G. King   +3 more
wiley   +1 more source

High Cell Density Perfusion Process of Quail Cells Producing Oncolytic rVSV‐NDV

Engineering in Life Sciences, Volume 25, Issue 7, July 2025.
ABSTRACT Oncolytic viruses as agents for the treatment of various types of cancer have demonstrated their potential in many clinical studies over the past decades. In particular, rVSV‐NDV (a recombinant vesicular stomatitis virus [VSV] construct with fusogenic Newcastle disease virus glycoproteins) shows promising preclinical results.
Lennart Jacobtorweihe, Sven Göbel, Markus Wolschek, Jennifer Altomonte, Udo Reichl, Yvonne Genzel   +5 more
wiley   +1 more source

Poxvirus-based vector systems and the potential for multi-valent and multi-pathogen vaccines

Expert Review of Vaccines, 2018
Introduction: With the increasing number of vaccines and vaccine-preventable diseases, the pressure to generate multi-valent and multi-pathogen vaccines grows.
Natalie A. Prow, Rocio Jimenez Martinez, John D. Hayball, Paul M. Howley, Andreas Suhrbier   +4 more
doaj   +1 more source

Vaccines against mpox: MVA-BN and LC16m8

Expert Review of Vaccines
Introduction Global outbreaks involving mpox clade IIb began in mid-2022. Today, clade IIb and clade I outbreaks continue. Reliable mpox vaccines can prevent serious mpox disease and death.Areas covered Globally, two vaccines hold mpox indications ...
John D. Grabenstein, Adam Hacker
doaj   +1 more source

Gene Expression Driven by a Strong Viral Promoter in MVA Increases Vaccination Efficiency by Enhancing Antibody Responses and Unmasking CD8+ T Cell Epitopes

Vaccines, 2014
Viral vectors are promising tools for vaccination strategies and immunotherapies. However, CD8+ T cell responses against pathogen-derived epitopes are usually limited to dominant epitopes and antibody responses to recombinant encoded antigens (Ags) are ...
Pablo D. Becker, Miriam Nörder, Sebastian Weissmann, Ronny Ljapoci, Volker Erfle, Ingo Drexler, Carlos A. Guzmán   +6 more
doaj   +1 more source

Safety and immunogenicity of a synthetic multiantigen modified vaccinia virus Ankara-based COVID-19 vaccine (COH04S1): an open-label and randomised, phase 1 trial [PDF]

, 2022
Flavia Chiuppesi, John A Zaia, Paul H Frankel, Rodica Stan, Jennifer Drake, Brenda Williams, Anne Marie Acosta, Karyn Francis, Randy A Taplitz, Janet K Dickter, Sanjeet Dadwal, Alfredo G Puing, Deepa D Nanayakkara, Patricia Ash, Yujie Cui, Heidi Contreras, Corinna La Rosa, Katrin Tiemann, Yoonsuh Park, Joybelle Medina, Angelina Iniguez, Qiao Zhou, Veronica Karpinski, Daisy Johnson, Katelyn Faircloth, Teadora Kaltcheva, Jenny Nguyen, Mindy Kha, Vu H Nguyen, Sandra Ortega Francisco, Alba Grifoni, Angela Wong, Alessandro Sette, Felix Wussow, Don J Diamond   +34 more
openalex   +1 more source

A Recombinant Modified Vaccinia Ankara Vaccine Encoding Epstein–Barr Virus (EBV) Target Antigens: A Phase I Trial in UK Patients with EBV-Positive Cancer [PDF]

, 2014
Graham S. Taylor, Hui Jia, Kevin J. Harrington, Lip Wai Lee, James Turner, Kristin Ladell, David A. Price, Manjit Tanday, Jen Matthews, Claudia Roberts, Ceri Edwards, Lesley McGuigan, A. Hartley, Steve Wilson, Edwin P. Hui, Anthony T.�C. Chan, Alan B. Rickinson, Neil Steven   +17 more
openalex   +1 more source

Isolation of vaccinia MVA recombinants using the viral F13L gene as the selective marker

BioTechniques, 2005
Modified vaccinia Ankara (MVA) is a highly attenuated vaccine vector that has an excellent vaccine safety record. Also, as a eukaryotic gene expression vector, MVA can be used in a biosafety level 1 setup, in contrast to more virulent vaccinia virus ...
Juana M. Sánchez-Puig, Rafael Blasco
doaj   +1 more source

Hazard Characterization of Modified Vaccinia Virus Ankara Vector: What Are the Knowledge Gaps?

Viruses, 2017
Modified vaccinia virus Ankara (MVA) is the vector of choice for human and veterinary applications due to its strong safety profile and immunogenicity in vivo.
Malachy I. Okeke, Arinze S. Okoli, Diana Diaz, Collins Offor, Taiwo G. Oludotun, Morten Tryland, Thomas Bøhn, Ugo Moens   +7 more
doaj   +1 more source